Hepatitis C cirrhosis
Conditions
Interventions
1:pegylated interferon alpha-2b plus ribavirin
1:symptomatic treatment
2:symptomatic treatment
Sponsors
302 Military Hospital of China
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Cirrhotic patients with chronic HCV infection based on diagnostic criteria of 2004 China clinical practice guidelines of chronic hepatitis C; 2. Males or females with age from 18 to 60 years old, capable of signing the informed consent; 3. Patients with HCV RNA more than 10^3 IU/ml; WBC more than 2.0*10^9/L; NE more than at least 1.0*10^9/L; PLT more than 60*10^9/L; HGB more than 100 g/L; 4. Patients with Child-Pugh A or B; BIL less than 2*ULN;BMI less than 28 kg/m^2.
Exclusion criteria
Exclusion criteria: a.Patients combined with other virus infection, liver failure, Child-Pugh C class, liver tumor, cardio-cerebrovascular disease, The blood system disease, or psychiatric disorders; b.Patients enrolled in other clinical trials; c.Patients with poor compliance or other factors which may lead to mistakes in determine of effect or safety; d.Allergy, pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HCV RNA undetectable rate;histological improvment rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| safety evaluation;HCC rate;liver function decompensated rate; | — |
Countries
China
Contacts
Public ContactChen Guofeng
Outcome results
None listed